Celcuity LLC
Celcuity Inc., a clinical-stage biotechnology company, focuses on the development of targeted therapies for the treatment of various solid tumors in the United States. The company's lead drug candidate includes Gedatolisib, which selectively targets various Class I isoforms of phosphatidylinositol-3-kinase (PI3K) and the two mechanistic targets of rapamycin (mTOR) sub-complexes, mTORC1 and mTORC2… Read more
Celcuity LLC (CELC) - Net Assets
Latest net assets as of September 2025: $116.96 Million USD
Based on the latest financial reports, Celcuity LLC (CELC) has net assets worth $116.96 Million USD as of September 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($476.00 Million) and total liabilities ($359.04 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $116.96 Million |
| % of Total Assets | 24.57% |
| Annual Growth Rate | 41.7% |
| 5-Year Change | 888.01% |
| 10-Year Change | N/A |
| Growth Volatility | 199.54 |
Celcuity LLC - Net Assets Trend (2015–2024)
This chart illustrates how Celcuity LLC's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Celcuity LLC (2015–2024)
The table below shows the annual net assets of Celcuity LLC from 2015 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | $115.62 Million | -17.28% |
| 2023-12-31 | $139.77 Million | +4.48% |
| 2022-12-31 | $133.77 Million | +94.69% |
| 2021-12-31 | $68.71 Million | +487.16% |
| 2020-12-31 | $11.70 Million | -39.36% |
| 2019-12-31 | $19.30 Million | -23.87% |
| 2018-12-31 | $25.35 Million | -19.25% |
| 2017-12-31 | $31.39 Million | +459.40% |
| 2016-12-31 | $5.61 Million | +11.86% |
| 2015-12-31 | $5.02 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Celcuity LLC's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 26683411500.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $37.14K | 0.03% |
| Other Components | $387.44 Million | 335.10% |
| Total Equity | $115.62 Million | 100.00% |
Celcuity LLC Competitors by Market Cap
The table below lists competitors of Celcuity LLC ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
SUNRISE N
SW:SUNN
|
$3.53 Billion |
|
Fuzhou Rockchip Electronics Co Ltd
SHG:603893
|
$3.53 Billion |
|
Sumitomo Chemical Company Limited
PINK:SOMMF
|
$3.53 Billion |
|
Jiangsu Nata Opto Electr Material
SHE:300346
|
$3.53 Billion |
|
HKT Trust and HKT Limited
PINK:HKTTF
|
$3.52 Billion |
|
Avanza Bank Holding AB (publ)
ST:AZA
|
$3.52 Billion |
|
PETRONAS Gas Berhad
PINK:PNAGF
|
$3.52 Billion |
|
Davide Campari-Milano N.V
PINK:DVDCF
|
$3.52 Billion |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Celcuity LLC's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 139,769,322 to 115,619,035, a change of -24,150,287 (-17.3%).
- Net loss of 111,779,105 reduced equity.
- New share issuances of 63,608,215 increased equity.
- Other comprehensive income increased equity by 854.
- Other factors increased equity by 24,019,749.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-111.78 Million | -96.68% |
| Share Issuances | $63.61 Million | +55.02% |
| Other Comprehensive Income | $854.00 | +0.0% |
| Other Changes | $24.02 Million | +20.77% |
| Total Change | $- | -17.28% |
Book Value vs Market Value Analysis
This analysis compares Celcuity LLC's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 38.93x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has decreased from 143.61x to 38.93x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2015-12-31 | $0.79 | $114.11 | x |
| 2016-12-31 | $0.84 | $114.11 | x |
| 2017-12-31 | $4.21 | $114.11 | x |
| 2018-12-31 | $2.50 | $114.11 | x |
| 2019-12-31 | $1.89 | $114.11 | x |
| 2020-12-31 | $1.14 | $114.11 | x |
| 2021-12-31 | $5.13 | $114.11 | x |
| 2022-12-31 | $8.68 | $114.11 | x |
| 2023-12-31 | $5.90 | $114.11 | x |
| 2024-12-31 | $2.93 | $114.11 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Celcuity LLC utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -96.68%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 0.00%
- • Asset Turnover: 0.00x
- • Equity Multiplier: 2.12x
- Recent ROE (-96.68%) is below the historical average (-48.82%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2015 | -45.08% | 0.00% | 0.00x | 1.06x | $-2.76 Million |
| 2016 | -58.99% | 0.00% | 0.00x | 1.08x | $-3.87 Million |
| 2017 | -19.92% | 0.00% | 0.00x | 1.02x | $-9.39 Million |
| 2018 | -29.51% | 0.00% | 0.00x | 1.03x | $-10.02 Million |
| 2019 | -38.14% | 0.00% | 0.00x | 1.05x | $-9.29 Million |
| 2020 | -80.96% | 0.00% | 0.00x | 1.11x | $-10.64 Million |
| 2021 | -43.09% | 0.00% | 0.00x | 1.25x | $-36.48 Million |
| 2022 | -30.18% | 0.00% | 0.00x | 1.31x | $-53.75 Million |
| 2023 | -45.63% | 0.00% | 0.00x | 1.37x | $-77.76 Million |
| 2024 | -96.68% | 0.00% | 0.00x | 2.12x | $-123.34 Million |
Industry Comparison
This section compares Celcuity LLC's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $59,082,939
- Average return on equity (ROE) among peers: -341.19%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Celcuity LLC (CELC) | $116.96 Million | -45.08% | 3.07x | $3.53 Billion |
| Aadi Bioscience Inc (AADI) | $-124.24K | 0.00% | 0.00x | $17.03 Million |
| America Great Health (AAGH) | $-992.37K | 0.00% | 0.00x | $2.12 Million |
| Ascentage Pharma Group International (AAPG) | $70.63 Million | -1310.51% | 34.40x | $2.25 Billion |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-27.92 Million | 0.00% | 0.00x | $59.18 Million |
| ABIVAX Société Anonyme (AAVXF) | $196.01 Million | -75.37% | 0.67x | $377.86 Million |
| Abcellera Biologics Inc (ABCL) | $10.25 Million | -21.57% | 1.29x | $738.02 Million |
| Abeona Therapeutics Inc (ABEO) | $489.00K | -1919.02% | 38.85x | $202.79 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $188.78 Million | -22.70% | 0.04x | $108.65 Million |
| Abpro Holdings, Inc. (ABP) | $-22.46 Million | 0.00% | 0.00x | $2.00 Million |
| Absci Corp (ABSI) | $176.18 Million | -62.76% | 0.23x | $345.85 Million |